Answers are grounded in this paper and cite their sources.
Accumulating evidence indicates that local immunometabolic crosstalk plays a critical role in the pathogenesis of diabetic nephropathy (DN). However, the specific contribution of tissue-resident innate immunity during the early stages of the disease remains poorly understood. Here, we identify that renal tissue-resident natural killer cells (trNKs) undergo a marked early accumulation coupled with pronounced immunometabolic hyperactivation, which acts as a key driver of tubular injury in early DN. Through flow cytometry and functional analyses, we reveal that renal trNKs selectively expand in early DN and exhibit a unique hybrid hypermetabolic state characterized by the concurrent enhancement of glycolysis and oxidative phosphorylation. This bioenergetic adaptation orchestrated by pyruvate carboxylase ( Pcx )-mediated tricarboxylic acid (TCA) cycle anaplerosis bypassing metabolic blockade and synergizing with myelocytomatosis oncogene (Myc) -driven transcriptional co-activation, fuels hyperactivated trNKs effector functions, notably driving inflammatory injury to neighboring tubular cells. Mechanistically, we attribute this hypermetabolic transition to upregulation of the aconitate decarboxylase 1 (ACOD1)-itaconate pathway, which paradoxically acts as a local metabolic amplifier rather than an anti-inflammatory brake in this context. Crucially, NK cell-specific deletion of Acod1 (Ncr1-iCre Acod1 fl/fl ) or targeted metabolic intervention markedly attenuates early tubular damage. Collectively, our findings uncover a model of early renal trNKs accumulation and immunometabolic hyperactivation driving DN progression, highlighting local immunometabolic targeting as a promising therapeutic strategy for early DN.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: